secwatch.observer — SEC 8-K summary
======================================

Issuer:     Bluejay Diagnostics, Inc. (BJDX)
CIK:        0001704287
Form:       8-K
Filed at:   2023-03-20T23:59:59+00:00
Accession:  0001213900-23-021408
Event type: earnings
Sentiment:  negative
Materiality: 0.75
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Bluejay Diagnostics reports 2022 net loss $9.3M; FDA submission delayed to H1 2024
--------------------------------------------------------------------------------

- Net loss $9.3M ($0.46 per share) vs $3.5M ($0.41 per share) in 2021.
- Cash and cash equivalents $10.1M, down from $19.0M year-over-year.
- R&D expense increased 262% to support clinical trials for planned FDA submission.
- FDA feedback requires expanded clinical study; de novo submission timeline pushed to H1 2024.
- Company to require additional funding to reach commercialization due to delay.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1704287/000121390023021408/0001213900-23-021408-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1704287/000121390023021408/ea175516-8k_bluejay.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-021408

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer